We found that the compound-mediated cytotoxic effect against colon cancer cells was greatly improved by the concomitant inhibition of NRF2 and BiP, highlighting a critical interplay between these two molecules and their pathways that cancer cells exploit to resist to the cytotoxic effect of the anticancer therapies. Here, HSPA5 is linked to colonic neoplasm.